We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Oncology

Oncology

Ask MedXY AI
What is the latest evidence?Key clinical updatesGuideline changes

Latest news

TAF2 in Hepatocellular Homeostasis and Tumorigenesis: Navigating the 8q24.12 Amplicon in Liver Cancer
Clinical Updates8q24.12 Amplificationhepatocellular carcinoma

TAF2 in Hepatocellular Homeostasis and Tumorigenesis: Navigating the 8q24.12 Amplicon in Liver Cancer

By MedXY|Mar 11, 2026

This review explores the dual role of TAF2 as a basal transcription factor essential for hepatocyte survival and an oncogenic driver in hepatocellular carcinoma when overexpressed via 8q24.12 amplification.

Universal ESD for Large Barrett’s Cancers: Shifting the Paradigm Toward Curative R0 Resection
GastroenterologyBarrett's esophagusEMR vs ESD

Universal ESD for Large Barrett’s Cancers: Shifting the Paradigm Toward Curative R0 Resection

By MedXY|Mar 10, 2026

A multicenter study demonstrates that prioritizing endoscopic submucosal dissection (ESD) for Barrett’s cancers >15mm significantly improves R0 resection rates and survival, particularly in T1b disease, compared to traditional endoscopic

GnRH Antagonists May Spare the Heart: Evidence of Reduced Coronary Plaque Progression in Prostate Cancer Patients
CardiologyCardio-OncologyCoronary Atherosclerosis

GnRH Antagonists May Spare the Heart: Evidence of Reduced Coronary Plaque Progression in Prostate Cancer Patients

By MedXY|Mar 9, 2026

A randomized clinical trial indicates that the GnRH agonist leuprolide significantly accelerates coronary plaque progression compared to the antagonist relugolix in men with prostate cancer, suggesting a potential biological mechanism for d

Global Diversity in Autoimmune Gastritis: Deciphering Regional Phenotypes and Neoplastic Risks
GastroenterologyGastric Cancerneuroendocrine tumors

Global Diversity in Autoimmune Gastritis: Deciphering Regional Phenotypes and Neoplastic Risks

By MedXY|Mar 9, 2026

An international multicentre study of 1,240 patients reveals that autoimmune gastritis presentation varies by region, with distinct risk factors—including age, intestinal metaplasia, and extreme hypergastrinemia—driving the development of g

New Consensus on APC Mosaicism: Transforming the Diagnosis and Management of Unexplained Polyposis
Gastroenterologycolorectal cancergastroenterology

New Consensus on APC Mosaicism: Transforming the Diagnosis and Management of Unexplained Polyposis

By MedXY|Mar 9, 2026

A landmark study in Gastroenterology reveals that APC mosaicism accounts for nearly 10% of unexplained colorectal polyposis. New guidelines recommend specific testing thresholds and surveillance strategies to prevent colorectal cancer in th

Long-Term Survival Gains with Tislelizumab: Redefining First-Line Therapy for Metastatic Nasopharyngeal Carcinoma
newsimmunotherapynasopharyngeal carcinoma

Long-Term Survival Gains with Tislelizumab: Redefining First-Line Therapy for Metastatic Nasopharyngeal Carcinoma

By MedXY|Mar 9, 2026

The 3-year follow-up of the RATIONALE-309 trial demonstrates that first-line tislelizumab plus chemotherapy significantly improves overall survival (45.3 months) in recurrent or metastatic nasopharyngeal carcinoma, identifying B-cell signat

Unmasking DARS1: A Dual-Action Driver of Hepatocellular Carcinoma Aggressiveness via SAGA-MYC Signaling
Gastroenterologyhepatocellular carcinomaliquid biopsy

Unmasking DARS1: A Dual-Action Driver of Hepatocellular Carcinoma Aggressiveness via SAGA-MYC Signaling

By MedXY|Mar 8, 2026

Researchers have identified DARS1 as a critical oncogenic driver in hepatocellular carcinoma. Beyond its role in protein synthesis, DARS1 enters the nucleus to modulate MYC signaling through the SAGA complex, offering a new therapeutic vuln

The Tryptophan Tug-of-War: How Faecalibacterium prausnitzii Counteracts Bacteroides fragilis in Colorectal Cancer
Gastroenterologycolorectal cancergut microbiome

The Tryptophan Tug-of-War: How Faecalibacterium prausnitzii Counteracts Bacteroides fragilis in Colorectal Cancer

By MedXY|Mar 8, 2026

A comprehensive multi-omics study reveals that Faecalibacterium prausnitzii metabolizes tryptophan into picolinic acid, which antagonizes the pro-tumorigenic effects of enterotoxigenic Bacteroides fragilis by down-regulating TCERG1 and CKAP

Adjuvant Imatinib Significantly Extends Survival and Delays Recurrence in KIT Exon 9-Mutant GIST: Evidence from a Global Multicenter Cohort
Gastroenterologyprecision oncology

Adjuvant Imatinib Significantly Extends Survival and Delays Recurrence in KIT Exon 9-Mutant GIST: Evidence from a Global Multicenter Cohort

By MedXY|Mar 7, 2026

This international multicenter study demonstrates that adjuvant imatinib therapy significantly improves both recurrence-free and overall survival in patients with resected KIT exon 9-mutant GIST, providing clarity on optimal management for

Optimizing Immunotherapy in Cholangiocarcinoma: Low-Dose Chemotherapy as a Catalyst for Immune Microenvironment Remodeling
Clinical UpdatesCholangiocarcinomaimmunotherapy

Optimizing Immunotherapy in Cholangiocarcinoma: Low-Dose Chemotherapy as a Catalyst for Immune Microenvironment Remodeling

By MedXY|Mar 7, 2026

This review examines how low-dose gemcitabine and cisplatin (LDGC) synergize with anti-PD-L1 therapy in intrahepatic cholangiocarcinoma by reprogramming immunosuppressive SPP1+ macrophages and enhancing CD8+ T-cell cytotoxicity through STAT

Beyond Mandatory Resection: Active Surveillance Proves Safe for RAS-Positive Thyroid Nodules
Diabetes & Endocrinologyactive surveillanceendocrinology

Beyond Mandatory Resection: Active Surveillance Proves Safe for RAS-Positive Thyroid Nodules

By MedXY|Mar 6, 2026

A new study suggests that isolated RAS mutations in Bethesda III and IV thyroid nodules do not always require surgery. With a 34% malignancy rate and low growth incidence, active surveillance emerges as a viable, safe alternative for approp

Genomic Therapy Matching in Rare and Refractory Cancers: Clinical Utility and Survival Outcomes from the MoST Program
Clinical Updatesbiomarkersgenomic profiling

Genomic Therapy Matching in Rare and Refractory Cancers: Clinical Utility and Survival Outcomes from the MoST Program

By MedXY|Mar 6, 2026

This review synthesizes findings from the Australian MoST program, demonstrating that genomically matched therapies significantly improve overall survival in advanced solid tumors only when supported by high-level prospective clinical trial

Patient-Centered Outcomes in Geriatric Oncology: Analyzing the Influence of Survival vs. Quality of Life Preferences in the GAP70+ Trial
Clinical Updatesadvanced cancergeriatric oncology

Patient-Centered Outcomes in Geriatric Oncology: Analyzing the Influence of Survival vs. Quality of Life Preferences in the GAP70+ Trial

By MedXY|Mar 6, 2026

A secondary analysis of the GAP70+ trial reveals that while 71.7% of older adults with advanced cancer prioritize quality of life, their clinical outcomes—including survival and toxicity—remain unchanged compared to those prioritizing survi

Questioning Routine Hormone Therapy: No Survival Benefit for Low-PSA Recurrent Prostate Cancer Undergoing Postoperative Radiotherapy
newshormone therapyoncology

Questioning Routine Hormone Therapy: No Survival Benefit for Low-PSA Recurrent Prostate Cancer Undergoing Postoperative Radiotherapy

By MedXY|Mar 6, 2026

A large-scale individual patient data meta-analysis suggests that adding hormone therapy to postoperative radiotherapy does not improve overall survival for patients with low PSA levels, prompting a re-evaluation of current treatment standa

Breaking the Wall: Can Intermittent Chemotherapy Overcome Primary Checkpoint Inhibitor Resistance in Metastatic Melanoma?
DermatologyCheckpoint Inhibitorsdrug resistance

Breaking the Wall: Can Intermittent Chemotherapy Overcome Primary Checkpoint Inhibitor Resistance in Metastatic Melanoma?

By MedXY|Mar 5, 2026

The multicentre phase II PROMIT trial demonstrates that intermittent dacarbazine can sensitize BRAF wildtype metastatic melanoma patients with primary ICI resistance to subsequent ICI rechallenge, yielding an 18% objective response rate and

SURE-02 Trial: Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Enable Bladder Preservation in Muscle-Invasive Disease
newsantibody-drug conjugatesimmunotherapy

SURE-02 Trial: Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Enable Bladder Preservation in Muscle-Invasive Disease

By MedXY|Mar 4, 2026

The SURE-02 phase 2 trial demonstrates that a combination of sacituzumab govitecan and pembrolizumab achieves a 39% clinical complete response rate in muscle-invasive bladder cancer, offering a promising bladder-sparing alternative for pati

Precision Dosing Without Compromise: UGT1A1 Genotype-Guided Irinotecan Dosing Maintains Survival in Gastrointestinal Cancers
GastroenterologyIrinotecanoncology

Precision Dosing Without Compromise: UGT1A1 Genotype-Guided Irinotecan Dosing Maintains Survival in Gastrointestinal Cancers

By MedXY|Mar 4, 2026

A multicentre cohort study confirms that upfront 30% irinotecan dose reductions for UGT1A1 poor metabolisers effectively prevent severe toxicity without compromising progression-free or overall survival in colorectal and pancreatic cancer p

The BMPR2 Nexus: How Breast Cancer Acts as a Second Hit for Pulmonary Hypertension
Cardiologybreast cancerCardio-Oncology

The BMPR2 Nexus: How Breast Cancer Acts as a Second Hit for Pulmonary Hypertension

By MedXY|Mar 2, 2026

Emerging evidence identifies a bidirectional link between breast cancer and pulmonary arterial hypertension (PAH) driven by BMPR2 signaling and IL-1β-mediated inflammation. This study suggests breast cancer may serve as a critical second hi

Surgical Management of Sporadic Medullary Thyroid Cancer: Evidence-Based Comparison of Total Thyroidectomy vs Lobectomy
Clinical UpdatesLobectomymedullary thyroid carcinoma

Surgical Management of Sporadic Medullary Thyroid Cancer: Evidence-Based Comparison of Total Thyroidectomy vs Lobectomy

By MedXY|Mar 2, 2026

This systematic review and meta-analysis suggests that thyroid lobectomy may offer comparable oncologic outcomes to total thyroidectomy for selected patients with sporadic medullary thyroid cancer, while significantly reducing postoperative

Beyond Objective Responses: Amivantamab Demonstrates Significant Clinical Benefit in Recurrent Adenoid Cystic Carcinoma
newsamivantamabtargeted therapy

Beyond Objective Responses: Amivantamab Demonstrates Significant Clinical Benefit in Recurrent Adenoid Cystic Carcinoma

By MedXY|Mar 2, 2026

A Phase 2 clinical trial of amivantamab, an EGFR-MET bispecific antibody, in recurrent or metastatic adenoid cystic carcinoma (ACC) showed a 72.2% clinical benefit rate. While the primary objective response rate was low, the high rate of di

Prev
21 / 25
1…1920212223…25
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities

Browse by specialty

Open language-specific specialty feeds and department pages.

news6629 articlesCardiology1375 articlesClinical Updates1288 articlesOncology1139 articlesDiabetes & Endocrinology842 articlesNeurology820 articlesPublic Health595 articlesGastroenterology572 articles
Hematology-Oncology
487 articles
Pediatrics484 articles
Internal Medicine444 articles